Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...

Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...

Merck (NYSE:MRK) announced Tuesday that a subcutaneously delivered version of its blockbuster cancer therapy pembrolizumab ...

Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, ...

Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

The Rebecca Foundation, in collaboration with Merck Foundation, has presented 30 brilliant but needy girls with school ...

In a significant move towards the liberalization of the healthcare sector, Shanghai's Pudong New Area witnessed the first ...

The pathology and radiology giant is recovering from its post-pandemic malaise and says earnings should improve this year ...

Within 10 years of Crohn's disease diagnosis, up to 50% of people will require surgery, with ileocaecal or ileocolonic resection being the most common procedure.1 Surgery is not curative and disease ...

The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...

We’re joining the National Foundation for Infectious Diseases to raise awareness among U.S. adults, ages 50 and older, about ...